Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study
Authors' conclusion
MACE are frequent and occur early in patients with AML treated with HMA-VEN, particularly in patients with diabetes, and are associated with lower survival.
Study context
- Population
- Adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) treated with hypomethylating agents and venetoclax (HMA-VEN) across 6 U.S. health care systems, January 2017 to July 2024adults (mean age 69 ± 12.5 years, 57% male)
- Participants
- 1,012 adults
- Exposure
- Patients with major adverse cardiovascular events (MACE) vs without MACE
- MACEn = 200
- Outcome
- MACE:
- Atrial fibrillation
- Heart failure
- Left ventricular ejection fraction reduction
- Stroke/transient ischemic attack
- Acute coronary syndrome
- Angina
- Ventricular tachycardia/fibrillation
- Myocarditis
- Cardiovascular death
Main finding
As reported in the abstract
- MACE occurred
- 20% of patients (n = 200)
- Median time to first MACE
- 120 days
- 12-month cumulative incidence
- 17%
- Atrial fibrillation
- 6%
- Stroke/transient ischemic attack
- 5%
- Left ventricular ejection fraction reduction
- 5%
- Heart failure
- 4%
Observational data: associations, not effects.
Secondary outcomes
Diabetes as independent predictor of MACE
| Subdistribution HR (95% CI) | P value | ||
|---|---|---|---|
| DiabetesFine-Gray competing risk model | 1.4 (1.03–1.89) | P = 0.031 | |
| 0.512Subdistribution hazard ratio (log scale) |
Mortality in patients with MACE
| HR (95% CI) | P value | ||
|---|---|---|---|
| MACEMortality 73% vs 56% · matched cohort | 1.96 (1.59–2.42) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study. JACC Adv. Published June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →